North America SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country (US and Canada) – Market Forecast, 2025–2034
The North America SGLT2 inhibitors market size is expected to reach USD 16.37 billion by 2034, according to a new study by Polaris Market Research. The report “North America SGLT2 Inhibitors Market Share, Size, Trends, Industry Analysis Report: By Indication [Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others], Drug, Distribution Channel, and Country; Segment Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increasing prevalence of type 2 diabetes has led to a substantial demand for effective treatments. Lifestyle factors such as poor diet, sedentary behavior, and rising obesity rates have contributed to the rising number of disease cases, highlighting the need for advanced therapeutic options.
SGLT2 inhibitors, presented by leading drugs such as Jardiance (Empagliflozin), have garnered widespread acceptance due to their dual benefits. These medications effectively manage blood glucose levels and offer significant cardiovascular and renal protection. Clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of major cardiovascular events, heart failure hospitalization, and the progression of chronic kidney disease, making them preferred options for healthcare providers.
Regulatory approvals, notably from the US Food and Drug Administration (FDA) and other regulatory bodies, have played a pivotal role in expanding the market. SGLT2 inhibitors have been approved for multiple indications, including heart failure and chronic kidney disease, beyond their primary use for glycemic control in type 2 diabetes. This expanded therapeutic scope has significantly increased their adoption. Increasing awareness among healthcare providers and patients about the benefits of SGLT2 inhibitors is leading to their increased acceptance and use. Additionally, ongoing research and development have led to the introduction of new SGLT2 inhibitors and combination therapies, further driving the North America SGLT2 inhibitors market expansion.
The advanced healthcare infrastructure in North America, characterized by well-established healthcare systems and advanced medical facilities, has facilitated the widespread use of these medications. Favorable insurance coverage and reimbursement policies have made SGLT2 inhibitors more accessible to patients, reducing financial barriers to treatment.
North America SGLT2 Inhibitors Market Report Highlights
By drug, in 2024, the Jardiance (Empagliflozin) segment accounted for the largest revenue share of the North America SGLT2 inhibitors market. Jardiance's robust clinical profile demonstrates significant benefits in reducing cardiovascular mortality and heart failure hospitalizations, making it a preferred choice for managing type 2 diabetes and associated cardiovascular risks.
The type 2 diabetes segment, based on indication, is expected to register the highest CAGR during the forecast period. Governments and healthcare organizations in North America implement policies and programs aimed at diabetes prevention, education, and treatment.
In 2024, the US accounted for a larger share of the North America SGLT2 inhibitors market. Pharmaceutical companies in the country invest significantly in research and development (R&D) to enhance the efficacy, safety, and usability of SGLT2 inhibitors.
A few key market players are AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and Pfizer Inc.
Polaris Market Research has segmented the North America SGLT2 inhibitors market report on the basis of indication, drug, distribution channel, and country:
By Indication Outlook (Revenue – USD Billion, 2020–2034)
Cardiovascular
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Others
By Drug Outlook (Revenue – USD Billion, 2020–2034)
Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Other SGLT2 Inhibitors
By Distribution Channel Outlook (Revenue – USD Billion, 2020–2034)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country Outlook (Revenue – USD Billion, 2020–2034)
US
Canada
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. North America SGLT2 Inhibitors Market Insights
- 4.1. North America SGLT2 Inhibitors Market – Distribution Channel Snapshot
- 4.2. North America SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. The Rising Obesity Rate in North America is Driving Market Growth
- 4.2.1.2. Rising Pharmaceutical Innovation and Marketing Drive Market Outlook
- 4.2.2. Restraints and Challenges
- 4.2.2.1. Alternative Treatment Options
- 4.3. Porter’s Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
- 4.4. PESTEL Analysis
- 4.5. North America SGLT2 Inhibitors Market Distribution Channel Trends
- 4.6. Value Chain Analysis
- 4.7. COVID-19 Impact Analysis
- 5. North America SGLT2 Inhibitors Market, by Indication
- 5.1. Key Findings
- 5.2. Introduction
- 5.2.1. North America SGLT2 Inhibitors Market, by Indication, 2020–2034 (USD Billion)
- 5.3. Cardiovascular
- 5.3.1. North America SGLT2 Inhibitors Market, by Cardiovascular, by Country, 2020–2034 (USD Billion)
- 5.4. Chronic Kidney Disease (CKD)
- 5.4.1. North America SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Country, 2020–2034 (USD Billion)
- 5.5. Type 2 Diabetes
- 5.5.1. North America SGLT2 Inhibitors Market, by Type 2 Diabetes, by Country, 2020–2034 (USD Billion)
- 5.6. Others
- 5.6.1. North America SGLT2 Inhibitors Market, by Others, by Country, 2020–2034 (USD Billion)
- 6. North America SGLT2 Inhibitors Market, by Drug
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. North America SGLT2 Inhibitors Market, by Drug, 2020–2034 (USD Billion)
- 6.3. Farxiga (Dapagliflozin)
- 6.3.1. North America SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Country, 2020–2034 (USD Billion)
- 6.4. Inpefa (Sotagliflozin)
- 6.4.1. North America SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Country, 2020–2034 (USD Billion)
- 6.5.Invokana (Canagliflozin)
- 6.5.1. North America SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Country, 2020–2034 (USD Billion)
- 6.6. Jardiance (Empagliflozin)
- 6.6.1. North America SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Country, 2020–2034 (USD Billion)
- 6.5. Qtern (Dapagliflozin/Saxagliptin)
- 6.5.1. North America SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Country, 2020–2034 (USD Billion)
- 6.5. Other North America SGLT2 Inhibitors
- 6.5.1. North America SGLT2 Inhibitors Market, by Other North America SGLT2 Inhibitors, by Country, 2020–2034 (USD Billion)
- 7. North America SGLT2 Inhibitors Market, by Distribution Channel
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. North America SGLT2 Inhibitors Market, by Distribution Channel, 2020–2034 (USD Billion)
- 7.3. Hospital Pharmacies
- 7.3.1. North America SGLT2 Inhibitors Market, by Hospital Pharmacies, By Country, 2020–2034 (USD Billion)
- 7.4. Online Pharmacies
- 7.4.1. North America SGLT2 Inhibitors Market, by Online Pharmacies, By Country, 2020–2034 (USD Billion)
- 7.5. Retail Pharmacies
- 7.5.1. North America SGLT2 Inhibitors Market, by Retail Pharmacies, By Country, 2020–2034 (USD Billion)
- 8. North America SGLT2 Inhibitors Market, by Country
- 8.1. Key findings
- 8.2. Introduction
- 8.2.1. North America SGLT2 Inhibitors Market Assessment, By Country, 2020–2034 (USD Billion)
- 8.3. North America SGLT2 Inhibitors Market
- 8.3.1. North America SGLT2 Inhibitors Market, by Indication, 2020–2034 (USD Billion)
- 8.3.2. North America SGLT2 Inhibitors Market, by Distribution Channel, 2020–2034 (USD Billion)
- 8.3.3. North America SGLT2 Inhibitors Market, by Drug, 2020–2034 (USD Billion)
- 8.3.4. North America SGLT2 Inhibitors Market – US
- 8.3.4.1. US: SGLT2 Inhibitors Market, by Indication, 2020–2034 (USD Billion)
- 8.3.4.2. US: SGLT2 Inhibitors Market, by Distribution Channel, 2020–2034 (USD Billion)
- 8.3.4.3. US: SGLT2 Inhibitors Market, by Drug, 2020–2034 (USD Billion)
- 8.3.5. North America SGLT2 Inhibitors Market – Canada
- 8.3.5.1. Canada: SGLT2 Inhibitors Market, by Indication, 2020–2034 (USD Billion)
- 8.3.5.2. Canada.: SGLT2 Inhibitors Market, by Distribution Channel, 2020–2034 (USD Billion)
- 8.3.5.3. Canada: SGLT2 Inhibitors Market, by Drug, 2020–2034 (USD Billion)
- 9. Competitive Landscape
- 9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
- 9.2. Partnerships/Collaborations/Agreements/Exhibitions
- 10. Company Profiles
- 10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
- 10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
- 10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
- 10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
- 10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
- 10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
- 10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
- 10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
- 10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
- 10.10. Pfizer Inc.
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook